Zimmer Partners’s Genmab GMAB Stock Holding History

Zimmer Partners’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-750,000	Closed	-$16.7M	–	87
2019 Q4	$16.7M	Hold	750,000	–	–	0.23%	52
2019 Q3	$15.2M	Buy	+750,000	New	+$14.8M	0.17%	65

Other funds holding GMAB

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Zimmer Partners's GMAB Position: Q1 2020 in Review

Zimmer Partners sold out of Genmab (GMAB) in Q1 2020, closing a stake of 750,000 shares — an estimated $16.7M sold.

Zimmer Partners first reported a position in GMAB in Q3 2019 and held it in 2 quarters. The position peaked at $16.7M in Q4 2019. 142 funds tracked by Wall St. Rank hold GMAB as of Q1 2020.

Zimmer Partners reported no remaining Genmab position as of Q1 2020 after selling out during the quarter.
Zimmer Partners sold 750,000 Genmab shares in Q1 2020, an estimated $16.7M.
Zimmer Partners first reported a position in Genmab in Q3 2019 and held it in 2 quarters.
Zimmer Partners's Genmab position peaked at $16.7M in Q4 2019.
142 funds tracked by Wall St. Rank held Genmab as of Q1 2020.

Based on Zimmer Partners's 13F filing for Q1 2020, filed 15 May 2020.